Table 1.

Inhibition of [³H]-WIN-35,428 binding and [³H]-dopamine uptake by compounds at hDAT N2A neuroblastoma cells.

Compound	[3H]-WIN Binding Inhibition, Ki (nM)*	[3H]-DA Uptake Inhibition, IC50 (nM)*
(±)-1a, threo-methylphenidate	25 ± 1	156 ± 58
(±)-1b, 4-I-methylphenidate	14 ± 3a	11 ± 2b
(±)-1f, 3-I-methylphenidate	4.5 ± 1a	14 ± 5b
(±)-3a, p-N3-N-Bn-4-I-methylphenidate	363 ± 28a	2764 ± 196b,c
(±)-3b, m-N3-N-Bn-4-I-methylphenidate	2754 ± 169a	7966 ± 348b,c
(±)-3c, o-N3-N-Bn-4-I-methylphenidate	517 ± 65a	1232 ± 70b,c
(±)-3d, p-N3-N-Bn-3-I-methylphenidate	658 ± 70a	1828 ± 261b,c
(±)-3e, m-N3-N-Bn-3-I-methylphenidate	2056 ± 73a	4627 ± 238b,c
(±)-3f, o-N3-N-Bn-3-I-methylphenidate	1112 ± 163a	2696 ± 178b,c

^*Each K_i or IC₅₀ value represents data from at least three independent experiments with each data point on the curve performed in duplicate.

^aP<0.05 vs. K_i of (±)-1a, threo-44 methylphenidate;

^bP<0.05 vs. IC₅₀ of (±)-1a, threo-methylphenidate;

^cP<0.05 vs. its corresponding K_i.